An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Parathyroid hormone (Primary) ; Calcium
- Indications Hypoparathyroidism
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms PARALLAX
- Sponsors Shire
- 13 Dec 2017 Planned End Date changed from 1 Dec 2017 to 31 May 2019.
- 13 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 31 May 2019.
- 10 Jun 2017 Biomarkers information updated